Pre-made Zolbetuximab benchmark antibody ( Whole mAb, anti-CLDN18 therapeutic antibody, Anti-SFTA5/SFTPJ Antibody) for drug discovery and mechanism of action (MOA) research
Cat No.: GMP-Bios-ab-649
Pre-Made Zolbetuximab biosimilar, Whole mAb, Anti-CLDN18 Antibody: Anti-SFTA5/SFTPJ therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Zolbetuximab (development code IMAB362) is an experimental monoclonal antibody against isoform 2 of Claudin-18. It is under investigation for the treatment of gastrointestinal adenocarcinomas and pancreatic tumors. IMAB362 was developed by Ganymed Pharmaceuticals AG.
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
|Catalog No.||Package||Price(In USD)||Qty (Quantity)||Sum(In USD)|
|Products Name (INN Index)||Pre-Made Zolbetuximab biosimilar, Whole mAb, Anti-CLDN18 Antibody: Anti-SFTA5/SFTPJ therapeutic antibody|
|Highest_Clin_Trial (Jan '20)||Phase-III|
|100% SI Structure||None|
|99% SI Structure||None|
|95-98% SI Structure||None|
|Conditions Approved||Hodgkin's disease|
|Conditions Active||Cervical cancer;Non-small cell lung cancer;Breast cancer;Cancer;Ovarian cancer;Pancreatic cancer;Solid tumours|
|Conditions Discontinued||Solid tumours|